A Prospective Correlative Trial of Personalized Patient-Derived Xenograft (PDX or TumourGraft) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma
Patients with recurrent or metastatic sarcoma will be consented to develop a patient derived
xenograft (PDX or TumourGraft) model of their tumour to perform drug sensitivity testing. The
purpose of the study is to evaluate the accuracy of the patient derived xenograft (PDX)
model in predicting patient clinical response to the same drug treatment.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society